Elizabeth Chun

Elizabeth Chun, PhD

Research Associate in Biomedical Informatics

Elizabeth (Hye-Jung) Chun received her MSc and PhD in Bioinformatics (under the supervisions of Drs. Steven Jones and Marco Marra, respectively) from the University of British Columbia, Canada. As part of the NIH NCI’s Therapeutically Applicable Research that Generates Effective Therapy (TARGET) initiative, Chun’s doctoral research focused on molecular characterization of pediatric malignant rhabdoid tumors (MRTs) through integrative analyses of whole genome, transcriptome, DNA methylation and histone modification profiles. Her work led to identification of novel molecular subgroups and revealed potential application of immunotherapy in this cancer type with very few mutations. She continued her research as a postdoctoral research fellow in Dr. Marra’s lab, to identify genetic and epigenetic alterations in MRTs using long-read sequencing data. Prior to her graduate training, she worked as a computational biologist at Canada’s Michael Smith Genome Sciences Centre, performing data analyses and coordinating research activities for The Cancer Genome Atlas (TCGA) and the Development of Highly active Anti-Leukemia stem cell Therapy at California Institute of Regenerative Medicine (CIRM-HALT) projects. She joined the Park Lab in June 2022. In the Park Lab, she is continuing her research in cancer genomics and contributing her work in the Common Fund Data Ecosystem project.

Suppression of fibrin(ogen)-driven pathologies in disease models through controlled knockdown by lipid nanoparticle delivery of siRNA.
Authors: Juang LJ, Hur WS, Silva LM, Strilchuk AW, Francisco B, Leung J, Robertson MK, Groeneveld DJ, La Prairie B, Chun EM, Cap AP, Luyendyk JP, Palumbo JS, Cullis PR, Bugge TH, Flick MJ, Kastrup CJ.
View full abstract on Pubmed
Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury.
Authors: Williamson LM, Rive CM, Di Francesco D, Titmuss E, Chun HE, Brown SD, Milne K, Pleasance E, Lee AF, Yip S, Rosenbaum DG, Hasselblatt M, Johann PD, Kool M, Harvey M, Dix D, Renouf DJ, Holt RA, Nelson BH, Hirst M, Jones SJM, Laskin J, Rassekh SR, Deyell RJ, Marra MA.
NPJ Precis Oncol
View full abstract on Pubmed
The presence of tumour-infiltrating neutrophils is an independent adverse prognostic feature in clear cell renal cell carcinoma.
Authors: Tessier-Cloutier B, Twa DD, Marzban M, Kalina J, Chun HE, Pavey N, Tanweer Z, Katz RL, Lum JJ, Salina D.
J Pathol Clin Res
View full abstract on Pubmed
Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration.
Authors: Chun HE, Johann PD, Milne K, Zapatka M, Buellesbach A, Ishaque N, Iskar M, Erkek S, Wei L, Tessier-Cloutier B, Lever J, Titmuss E, Topham JT, Bowlby R, Chuah E, Mungall KL, Ma Y, Mungall AJ, Moore RA, Taylor MD, Gerhard DS, Jones SJM, Korshunov A, Gessler M, Kerl K, Hasselblatt M, Frühwald MC, Perlman EJ, Nelson BH, Pfister SM, Marra MA, Kool M.
Cell Rep
View full abstract on Pubmed
Comprehensive whole genome sequence analyses yields novel genetic and structural insights for Intellectual Disability.
Authors: Zahir FR, Mwenifumbo JC, Chun HE, Lim EL, Van Karnebeek CDM, Couse M, Mungall KL, Lee L, Makela N, Armstrong L, Boerkoel CF, Langlois SL, McGillivray BM, Jones SJM, Friedman JM, Marra MA.
BMC Genomics
View full abstract on Pubmed
ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis.
Authors: Zipeto MA, Court AC, Sadarangani A, Delos Santos NP, Balaian L, Chun HJ, Pineda G, Morris SR, Mason CN, Geron I, Barrett C, Goff DJ, Wall R, Pellecchia M, Minden M, Frazer KA, Marra MA, Crews LA, Jiang Q, Jamieson CHM.
Cell Stem Cell
View full abstract on Pubmed
Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways.
Authors: Chun HE, Lim EL, Heravi-Moussavi A, Saberi S, Mungall KL, Bilenky M, Carles A, Tse K, Shlafman I, Zhu K, Qian JQ, Palmquist DL, He A, Long W, Goya R, Ng M, LeBlanc VG, Pleasance E, Thiessen N, Wong T, Chuah E, Zhao YJ, Schein JE, Gerhard DS, Taylor MD, Mungall AJ, Moore RA, Ma Y, Jones SJM, Perlman EJ, Hirst M, Marra MA.
Cancer Cell
View full abstract on Pubmed
Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal.
Authors: Holm F, Hellqvist E, Mason CN, Ali SA, Delos-Santos N, Barrett CL, Chun HJ, Minden MD, Moore RA, Marra MA, Runza V, Frazer KA, Sadarangani A, Jamieson CH.
Proc Natl Acad Sci U S A
View full abstract on Pubmed
GLI2 inhibition abrogates human leukemia stem cell dormancy.
Authors: Sadarangani A, Pineda G, Lennon KM, Chun HJ, Shih A, Schairer AE, Court AC, Goff DJ, Prashad SL, Geron I, Wall R, McPherson JD, Moore RA, Pu M, Bao L, Jackson-Fisher A, Munchhof M, VanArsdale T, Reya T, Morris SR, Minden MD, Messer K, Mikkola HK, Marra MA, Hudson TJ, Jamieson CH.
J Transl Med
View full abstract on Pubmed
Loss of the Notch effector RBPJ promotes tumorigenesis.
Authors: Kulic I, Robertson G, Chang L, Baker JH, Lockwood WW, Mok W, Fuller M, Fournier M, Wong N, Chou V, Robinson MD, Chun HJ, Gilks B, Kempkes B, Thomson TA, Hirst M, Minchinton AI, Lam WL, Jones S, Marra M, Karsan A.
J Exp Med
View full abstract on Pubmed